Global Artificial Intelligence-driven Drug Development Supply, Demand and Key Producers, 2023-2029
The global Artificial Intelligence-driven Drug Development market size is expected to reach $ 8513.8 million by 2029, rising at a market growth of 29.3% CAGR during the forecast period (2023-2029).
Artificial intelligence (AI) has the potential to revolutionize the drug discovery process,
offering improved efficiency, accuracy, and speed.
This report studies the global Artificial Intelligence-driven Drug Development demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Artificial Intelligence-driven Drug Development, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Artificial Intelligence-driven Drug Development that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Artificial Intelligence-driven Drug Development total market, 2018-2029, (USD Million)
Global Artificial Intelligence-driven Drug Development total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Artificial Intelligence-driven Drug Development total market, key domestic companies and share, (USD Million)
Global Artificial Intelligence-driven Drug Development revenue by player and market share 2018-2023, (USD Million)
Global Artificial Intelligence-driven Drug Development total market by Type, CAGR, 2018-2029, (USD Million)
Global Artificial Intelligence-driven Drug Development total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Artificial Intelligence-driven Drug Development market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include IBM, Exscientia, Google(Alphabet), Microsoft, Atomwise, Schrodinger, Aitia, Insilico Medicine and NVIDIA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Artificial Intelligence-driven Drug Development market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Artificial Intelligence-driven Drug Development Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Artificial Intelligence-driven Drug Development Market, Segmentation by Type
Hardware
Software
Service
Global Artificial Intelligence-driven Drug Development Market, Segmentation by Application
Early Drug Discovery
Preclinical Phase
Clinical Phase
Regulatory Approval
Companies Profiled:
IBM
Exscientia
Google(Alphabet)
Microsoft
Atomwise
Schrodinger
Aitia
Insilico Medicine
NVIDIA
XtalPi
BPGbio
Owkin
CytoReason
Deep Genomics
Cloud Pharmaceuticals
BenevolentAI
Cyclica
Verge Genomics
Valo Health
Envisagenics
Euretos
BioAge Labs
Iktos
BioSymetrics
Evaxion Biotech
Aria Pharmaceuticals
Key Questions Answered
1. How big is the global Artificial Intelligence-driven Drug Development market?
2. What is the demand of the global Artificial Intelligence-driven Drug Development market?
3. What is the year over year growth of the global Artificial Intelligence-driven Drug Development market?
4. What is the total value of the global Artificial Intelligence-driven Drug Development market?
5. Who are the major players in the global Artificial Intelligence-driven Drug Development market?
6. What are the growth factors driving the market demand?